Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 April 2025 | Story Tshepo Tsotetsi | Photo Supplied
EMS PhDs
Dr Shaun Watson, Prof Philippe Burger, Dr Marese Lombard, and Dr Ambrosé Du Plessis.

As the University of the Free State (UFS) continues to celebrate the achievements of its graduates during the April 2025 graduation ceremonies, three academic staff members from the UFS Faculty of Economic and Management Sciences (EMS) are among those marking a significant milestone with the successful completion of their doctoral degrees.

Prof Philippe Burger, Dean of the EMS Faculty, reflected on the significance of the moment and applauded the trio of new EMS PhD graduates: Dr Shaun Watson, Dr Marese Lombard, and Dr Ambrosé Ray du Plessis.

“For the EMS Faculty to have three staff members obtain a PhD on one day is very special,” Prof Burger said. “These colleagues have grown their standing in the scholarly community and are now, with a PhD in the bag, ready to take on the academic world and the world at large. The EMS Faculty places a high premium on our staff holding a PhD, so we strongly encourage those who are not in possession of a PhD to pursue one.”

Prof Burger added that their achievements not only reflect personal dedication and professional growth but also contribute to the University of the Free State’s Vision 130 goal: to have 75% of academic staff holding doctoral degrees by 2034.

The EMS academics who graduated during the April 2025 ceremonies are:

 

Dr Shaun Watson: Understanding markets through restatements

Dr Shaun Watson, a senior lecturer in the UFS School of Accountancy since 2006, earned his PhD in Management Accounting with a thesis titled ‘Market Efficiency and Share Price Reaction Following the Retrospective Restatement of Financial Statements of JSE-Listed Companies’. His study analysed how financial restatements affect market behaviour, providing key insights for policymakers and investors navigating emerging markets.

“For me, it was both a personal challenge and a professional goal,” Dr Watson said. “I’d often wondered if I had what it takes to complete a PhD and, as an academic, I saw it as the pinnacle of our field. My wife was the one who told me to ‘Nike – just do it!’ Her belief in me, along with the quiet support of my family, gave me the push I needed to start, and the strength to keep going.”

To those still considering the journey, Watson offered this advice: “Do it for yourself – because if you don’t, you will never finish. It is a demanding journey that requires sacrifice and perseverance, but the reward of discovering something meaningful is worth every moment.”

 

Dr Marese Lombard: Taxation as a tool for sustainable agriculture

Also from the School of Accountancy, Dr Marese Lombard received her PhD in Taxation. Her research, ‘Taxation as a Method to Promote Sustainable Agriculture in South Africa’, is the first of its kind to offer empirical evidence on how tax provisions could be used to incentivise sustainability in local agriculture.

“I hope to see a conversation regarding policy changes as to how taxation can be used as a positive method to impact sustainability,” Dr Lombard said. “If taxation can be used to further assist our agricultural industry to become more sustainable, it can not only increase our competitive edge but also address the concern of food security.”

Reflecting on her personal growth, she said, “It has taught me that we are more resilient than we think. The challenge of taking on a PhD has made me more open to other ideas and approaches, and more comfortable with criticism – not just in academia, but in life.”

 

Dr Ambrosé Ray du Plessis: Rethinking the political-administrative divide

From the Department of Public Administration and Management, Dr Ambrosé Ray du Plessis earned his PhD in Public Administration and Management. His thesis, ‘The Political-Administrative Dichotomy in Coalition-Led Metropolitan Municipalities: A South African Perspective’, developed a fresh conceptual framework for understanding the tensions and complexities within coalition-led governance, using the City of Johannesburg as a case study.

“For me, academia is a calling, and I believe that a PhD is an essential stepping stone to be successful in academia,” Dr Du Plessis said. “Being the first in my family to do a PhD motivated me to work harder, as I wanted to inspire those who will come after me.”

Balancing full-time lecturing and doctoral research required immense discipline: “I often had to work at night and over weekends to meet my deadlines… but the emotional and intellectual support from my PhD promoter, Prof Liezel Lues, was central to my success.”

Now, Dr Du Plessis hopes to deepen academic discourse on coalition politics: “My research addresses critical gaps and provides fresh insights into the political-administrative discourse as it can be applied to real-world coalition government problems in South Africa… I hope my work can leave a lasting impact – not only within academia but also in practical applications that benefit society.”

 

A testament to resilience and purpose

While their research topics differ vastly, all three describe their PhD journeys as transformative, both professionally and personally. From late nights and weekend writing sessions to intense supervision relationships, each story reflects a deeper commitment to scholarship – and to growing the UFS’s intellectual capital.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept